PRS47 The Effect of Introduction of Generic Drugs on Patients’ Access To Pharmaceuticals In Hungary  by Répásy, B. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A177
PRS46
ImPRoved HealtH CaRe outComeS and CoSt SavIngS foR aStHma 
tHRougH taRgeted Home InteRventIonS
Norlien K.G.1, Carlson A.M.2, York P.V.1
1Minnesota Department of Health, St. Paul, MN, USA, 2Data Intelligence Consultants, LLC, Eden 
Prairie, MN, USA
Objectives: Studies have demonstrated the importance of the environment both 
on the development of asthma and on exacerbation of asthma symptoms in those 
who have been diagnosed with the disease. The goal of this project was to pro-
vide in-home asthma services that covered both self-management education and 
home environmental interventions for children diagnosed with asthma living in 
Section 8 Multi-family Housing. MethOds: This HUD-funded project consisted 
of 3-4 home visits by a public health nurse over a one year period—an in-home 
baseline visit; a visit to deliver allergen-reducing products if needed; and 6 and 
12-month follow-ups by phone or in-home visit. Data was collected on asthma 
status (health-related quality of life and asthma control), health service utilization 
(hospitalizations, ED and office visits) and school and/or work absences due to 
asthma. Data analysis was completed using SAS v9.3. Results: 219 children from 
161 low income families were enrolled from five participating local public health 
agencies in a large metropolitan area. The low cost interventions provided, resulted 
in significant increases in the proportion of enrollees experiencing minimal to no 
daytime and nighttime symptom burden and functional limitations at the 12-month 
follow-up (p< 0.05). Overall health care service use declined. There was a significant 
reduction in school days missed (p< 0.05), the equivalent of 5 school days per child 
per year. The average cost per family of interventions, was $424 (e.g. mattress and 
pillow encasements, HEPA vacuum cleaners, air purifiers). Program administra-
tive costs per family were $585 (e.g. enrollment costs, travel time, visit time and 
documentation). cOnclusiOns: This study provided additional support for the 
usefulness and success of providing home interventions for low income children 
who have been diagnosed with asthma. Low cost, targeted interventions led to 
improvements in HRQOL, decreased health service utilization, increased school 
attendance and a positive return on investment.
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Objectives: The aim of our study was to analyze the generic competition of medica-
ments containing the active substance montelukast sodium and to examine the 
cost-containment methods of the Hungarian National Health Insurance Fund 
Administration. MethOds: Data derived from the nationwide pharmaceutical 
database of Hungarian National Health Insurance Fund Administration (2007-2013). 
We analyzed the turnover and price of the medicaments containing the active sub-
stance montelukast sodium. Accordingly our indicators were: consumer price, social 
insurance subsidy, patients’ co-payment and defined daily dose (DOT). Results: 
The price of Singulair 10 mg tablets was 32 USD in October 2011, when the generics 
appeared, and it was reduced to 10 USD by the end of 2013. The generics started 
with a price 40% lower (for example Montelukast Teva 10 mg tablets: 19 USD, Eonic 
10 mg tablets: 17 USD, Montelukast Sandoz 10 mg tablets: 19 USD), their price was 
diminished below 7.4 by the end of 2013 (for example: Montelukast Teva 10 mg tablets: 
5.2 USD, Eonic 10 mg tablets: 5.8 USD, Montelukast Sandoz 10 mg tablets: 5.5 USD). 
The DOT increased gradually: In 2007 it was 1.7 million days, in 2010 6.3 million days 
and in 2013 it increased over 10 million days. The amount of the health insurance 
subsidy was 9.2 million USD in 2010. It reached its peak in 2011 (10.5 million USD) , in 
2012 it was reduced to 7 million USD, in 2013 to 4.1 million USD, in all it is a setback 
of 61%. cOnclusiOns: Following the introduction of generic drugs, the price of the 
medicaments containing montelukast sodium was significantly reduced. The annual 
health insurance subsidy was significantly reduced as well, while the DOT increased. 
The patients’ access to drugs containing montelukast sodium increased significantly.
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Objectives: Chronic obstructive pulmonary disease (COPD) is one of the most 
common lung diseases. COPD prevalence among US adults was estimated to be 
15 million or 6.3 percent of the total population in 2011. Nonadherence to COPD 
maintenance medications has been reported to be associated with more hospitaliza-
tions, higher mortality and lower quality of life. This study examined COPD mainte-
nance medication adherence among Medicare beneficiaries with COPD. MethOds: 
An observational, retrospective cohort study was conducted using 2007 and 2008 
Medicare Current Beneficiary Survey (MCBS) data. Sample inclusion criteria were 
being diagnosed with COPD and having at least two Medicare Part D claims. 
Medication adherence was measured by calculating proportion of days covered 
(PDC). PDC was calculated as the number of days with COPD maintenance medica-
tions available divided by total number of days in a six-month period following 
index dates, which were defined as the date of first COPD maintenance medica-
tion fill in 2007. A dichotomous variable was used to determine adherence status. 
Individuals with PDCs of 0.80 or greater were considered adherent and individuals 
with PDCs less than 0.80 were considered nonadherent. Logistic regressions were 
used to examine associations between demographic variables and medication 
adherence. Results: A total of 292 beneficiaries fulfilled sample selection criteria 
and were included in the analysis. The mean age was 72 years, 54 percent were ≤ 
75 years old and 11 percent were 85 years or older. The sample was predominantly 
female (60%) and white (85%). The mean±standard deviation PDC was 0.69±0.24. 
More than half (59%) of the Medicare beneficiaries had PDC of less than 0.80 and 
were classified as nonadherent to their COPD maintenance medications. No sig-
label prospective study was conducted among 208 COPD patients who were 
admitted in a tertiary care teaching hospital in south India after obtaining the 
ethical clearance. Demographics, medication adherence and quality of life 
of the patients were measured using Morisky scale (Adherence) & St. George 
Respiratory Questionnaire (HRQoL). Statistical analyses were performed using 
SPSS®version 20. Results: Mean age of the study population (n= 208) was 
58.42±9.72.(Males = 93.5%) . After the drug treatment, males showed statistically 
significant (p < 0.05) improvement in pulmonary function, medication adher-
ence and HRQoL. Patients with COPD duration of < 5 years showed a signifi-
cant improvement in pulmonary function and HRQoL scores. Literate patients 
had a significantly higher improvement in Medication Adherence and HRQoL 
than illiterate patients. cOnclusiOns: The results of the study suggest that 
demographic factors were independently associated with outcomes in COPD 
patients.
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Objectives: Tobacco smoking is the leading cause of preventable morbidity 
and mortality in the United States, and smoking cessation has multiple health 
benefits. The purpose of this study was to assess cigarette smokers’ preference 
towards characteristics of tobacco cessation medications using a Willingness-to-Pay 
approach. MethOds: Data from the 2008 Healthstyles Survey, a mail-based prob-
ability sample of 5,399 adult aged ≥ 18 years, were used to assess three primary out-
comes among current cigarette smokers (n= 914): 1) interest in quitting; 2) interest 
in using cessation medications; and 3) willingness to pay for six types of cessation 
medications. Point estimates and 95% confidence intervals were calculated overall 
and by sociodemographic and smoking behavior characteristics. Multivariate Probit 
regression analysis was used to evaluate smokers’ willingness to pay in relation 
to perceived importance of three cessation medication characteristics: conveni-
ence of use, over-the-counter availability, and efficiency to help quit. All models 
controlled for sociodemographic characteristics, smoking behavior characteristics, 
and U.S. region fixed effects. Results: Approximately 68.4% of current cigarette 
smokers were interested in quitting. Among these individuals, 45.6% indicated that 
they were interested in using cessation medications, and of these, 47.3% indicated 
that they were willing to pay $150 or more out-of-pocket for these medications. 
Convenience of use and the effectiveness of these medications to help quit were 
positively associated with current smokers’ willingness to pay for $300 or more 
(p≤ 5%); however, no association was observed for over-the-counter availability. 
Self-reported exposure to telephone quitline advertisements was also positively 
associated with the willingness-to-pay. cOnclusiOns: Approximately 68% of cur-
rent smokers are interested in quitting and about half of those smokers interested 
in quitting are also interested in using cessation medications. Convenience of use 
and the medication’s effectiveness are important to smokers with quit intentions. 
Understanding these preferences may help inform efforts to increase access and 
utilization of cessation medications.
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Objectives: Allergic asthma (AA) patients comprise over 93% of severe/difficult 
to treat cases in the US and patients face a lifelong treatment course. A dearth of 
real world information exists on the use of effective and approved treatments, 
particularly among adolescents. This study examined medication treatments for 
AA patients and incorporated treatment intensity (HighTx), consistent with NHLBI 
treatment guidance (steps 5-6), as a severity proxy. MethOds: This retrospec-
tive, observational study used MarketScan claims to identify newly diagnosed 
AA patients (10/2009 – 9/2012). Two cohorts were established: adolescents (12-17); 
adults (18-64). Index was the date of first AA diagnosis. Continuous enrollment 
was required for 12 months before and after index. Demographics and comorbidi-
ties were measured at baseline. Asthma medication use was observed in the 12 
months after index. HighTx was characterized for patients with high dose inhaled 
corticosteroid/long-acting beta agonist (ICS/LABA) combination treatment and 
having > 30 days supply in any continuous treatment period in 12 months after 
index. Results: Gender distribution differed across age cohorts (adolescents: 
> 50% female; adults: > 65% male). Acute illness drove comorbidity burden: more 
adolescents experienced acute respiratory infections (37.9% vs. 24.5% adult); more 
adults reflected acute sinusitis (20.6% vs. 25.2% adult). Treatment patterns (full 
sample): more adolescents received short-acting beta agonist (35.5% vs. 30.2% 
adults); fewer received ICS/LABA (22.6% vs. 34.5% adults) and monoclonal anti-
bodies (0.3% vs. 1.1% adults). Treatment pattern (HighTx): more patients received 
ICS/LABA (adolescents 98.9%; adults 99.3%); days on therapy did not exceed 160 
(ICS/LABA) for either HighTx age cohort. Twice as many HighTx adults received 
monoclonal antibodies as adolescents (2.5% vs. 5.1% adults). cOnclusiOns: In 
light of similar disease burden, AA diagnosis, and availability of effective treat-
ments, fewer AA adolescents received targeted therapies than adults. This dispar-
ity highlights the opportunity to incorporate targeted therapies as a treatment 
option, particularly for adolescent AA patients.
